OBJECTIVES: A "utility" is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities. METHODS: We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohort-a longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months. RESULTS: There were 257 patients (79% women; age=43+/-15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P<0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r=0.31; P<0.01), IBSSS (r=0.36; P<0.01), IBS-QOL (r=0.36; P<0.01), CDC-4 (r=0.44; P<0.01), WPAI presenteeism (r=0.16; P<0.01), abdominal pain (r=0.43; P<0.01), and distension (r=0.18; P=0.01). The utilities in patients reporting "considerable relief" of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P=0.02). CONCLUSIONS: EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.
OBJECTIVES: A "utility" is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities. METHODS: We analyzed data from Rome III IBSpatients in the Patient Reported Observed Outcomes and Function (PROOF) Cohort-a longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months. RESULTS: There were 257 patients (79% women; age=43+/-15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P<0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r=0.31; P<0.01), IBSSS (r=0.36; P<0.01), IBS-QOL (r=0.36; P<0.01), CDC-4 (r=0.44; P<0.01), WPAI presenteeism (r=0.16; P<0.01), abdominal pain (r=0.43; P<0.01), and distension (r=0.18; P=0.01). The utilities in patients reporting "considerable relief" of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P=0.02). CONCLUSIONS: EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.
Authors: Edward P Havranek; Teresa A Simon; Gilbert L'Italien; Allison Smitten; A Brett Hauber; Roland Chen; Pablo Lapuerta Journal: J Card Fail Date: 2004-08 Impact factor: 5.712
Authors: Lawrence J Brandt; William D Chey; Amy E Foxx-Orenstein; Lawrence R Schiller; Philip S Schoenfeld; Brennan M Spiegel; Nicholas J Talley; Eamonn M M Quigley Journal: Am J Gastroenterol Date: 2009-01 Impact factor: 10.864
Authors: Ron L Akehurst; John E Brazier; Nigel Mathers; Caroline O'Keefe; Eva Kaltenthaler; Anne Morgan; Maria Platts; Stephen J Walters Journal: Pharmacoeconomics Date: 2002 Impact factor: 4.981
Authors: J S Labus; R Bolus; L Chang; I Wiklund; J Naesdal; E A Mayer; B D Naliboff Journal: Aliment Pharmacol Ther Date: 2004-07-01 Impact factor: 8.171
Authors: Brennan M R Spiegel; Ian M Gralnek; Roger Bolus; Lin Chang; Gareth S Dulai; Emeran A Mayer; Bruce Naliboff Journal: Arch Intern Med Date: 2004-09-13
Authors: George F Longstreth; Alisa Wilson; Kevin Knight; John Wong; Chiun-Fang Chiou; Victoria Barghout; Feride Frech; Joshua J Ofman Journal: Am J Gastroenterol Date: 2003-03 Impact factor: 10.864
Authors: Brooks D Cash; Joel H Rubenstein; Patrick E Young; Andrew Gentry; Borko Nojkov; Dong Lee; A Hirsohi Andrews; Richard Dobhan; William D Chey Journal: Gastroenterology Date: 2011-07-14 Impact factor: 22.682
Authors: Christopher V Almario; Benjamin D Noah; Alma Jusufagic; Daniel Lew; Brennan M R Spiegel Journal: Clin Gastroenterol Hepatol Date: 2018-03-27 Impact factor: 11.382
Authors: B M R Spiegel; R Bolus; L A Harris; S Lucak; W D Chey; G Sayuk; E Esrailian; A Lembo; H Karsan; K Tillisch; J Talley; L Chang Journal: Aliment Pharmacol Ther Date: 2010-08-30 Impact factor: 8.171
Authors: B Spiegel; R Bolus; L A Harris; S Lucak; B Naliboff; E Esrailian; W D Chey; A Lembo; H Karsan; K Tillisch; J Talley; E Mayer; L Chang Journal: Aliment Pharmacol Ther Date: 2009-09-12 Impact factor: 8.171
Authors: Leyla Mohseninejad; Talitha Feenstra; Henriëtte E van der Horst; Hèlen Woutersen-Koch; Erik Buskens Journal: Eur J Health Econ Date: 2012-11-18